Welcome to our dedicated page for Wesana Health Holdings news (Ticker: WSNAF), a resource for investors and traders seeking the latest updates and insights on Wesana Health Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wesana Health Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wesana Health Holdings's position in the market.
Wesana Health Holdings announced positive results from an animal study examining the effects of psilocybin combined with imipramine in treating depression. The study showed that administering imipramine three weeks after a psilocybin dose resulted in a 39% improvement in depressive behaviors, while a second dose four weeks later led to a 45% reduction. This suggests potential for enhanced treatment options for depression. Additionally, Wesana has engaged MDM Worldwide for investor relations services at $8,000 per month for six months, plus stock compensation.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced progress in the clinical development of SANA-013, a novel therapy targeting Traumatic Brain Injury (TBI)-related major depressive disorder. Following a pre-Investigational New Drug (IND) meeting, the FDA provided positive feedback on requirements to advance to clinical studies. Wesana plans to initiate in-human trials in late 2022, leveraging a new psilocybin and cannabidiol therapy protocol aimed at delivering sustained therapeutic effects. The company aims to meet FDA guidelines in its ongoing development efforts.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced the construction of its third mental health clinic in Naperville, IL, expected to open in Spring 2022. The 3,000 square-foot facility will offer innovative psychiatric care, including ketamine therapy and Deep Transcranial Magnetic Stimulation for conditions like Major Depression. The investment for the clinic's build-out is approximately USD $250,000. Additionally, Wesana has entered into a sixty-day investor relations agreement with Future Money Trends LLC for USD $500,000 to enhance public awareness.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) has appointed Meghna A. Gaeta as Chief Marketing Officer to lead its marketing strategy. Gaeta, with over 18 years of experience in healthcare and technology marketing, aims to bridge the gap between patients and providers, enhancing Wesana's position in mental health care delivery. The company has also engaged North Equities for investor communications, paying $70,000 in restricted stock units. These strategic moves are expected to bolster Wesana's clinical network and market presence.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announces positive results from an animal study on its innovative depression treatment protocol. The study showed that a single high dose of psilocybin leads to rapid improvements in depressive behaviors for up to 14 days. Following this, a maintenance regimen combining microdoses of psilocybin and cannabidiol resulted in an additional 64% reduction in depressive behaviors. This protocol is being evaluated for major depressive disorder associated with traumatic brain injury, marking a significant step forward in mental health treatment.
Wesana Health Holdings (OTCQB: WSNAF) recently announced key updates regarding its Care Development and Care Delivery strategies. The FDA has granted a pre-IND meeting for its drug candidate SANA-013 aimed at treating TBI-related major depressive disorder, scheduled for March 11, 2022. Wesana Clinics reported record performance in Q4, with significant increases in patient visits and telemedicine use. A new flagship clinic is set to open in late Q1 2022, and the company is implementing a restructuring program expected to reduce overhead by $1.1M to enhance operational efficiency.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) announced a pre-IND meeting with the U.S. FDA for its therapy SANA-013 targeting Traumatic Brain Injury (TBI) related major depressive disorder (MDD). Scheduled for March 11, 2022, this meeting will provide feedback on the company's toxicology program before initiating a Phase I clinical trial, expected late 2022. CEO Daniel Carcillo emphasized the urgency for effective treatments, noting existing therapies achieve only a 30-40% success rate.
Wesana aims to enhance neuroplasticity and neurogenesis using a combination of psilocybin and CBD.
Wesana Health announced positive results from a commercial viability analysis by the Boston Consulting Group (BCG), confirming the potential for MDMA-assisted therapy in treating traumatic brain injury (TBI). The findings bolster partnership discussions with the Multidisciplinary Association for Psychedelic Studies (MAPS). CEO Daniel Carcillo highlighted the report's impact on the development of therapies for TBI, an issue costing the US ~$76.5 billion annually. The collaboration aims to expedite research timelines and enhance access to this promising treatment.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) has filed a Patent Cooperation Treaty (PCT) application for protocols and delivery methods utilizing psilocybin-assisted psychotherapy to treat neurological conditions, including traumatic brain injury (TBI) symptoms like depression and anxiety. The application aims for protection in major global markets. CEO Daniel Carcillo expressed excitement over this step towards innovative therapies, while Chief Scientific Officer Dr. Mark Wingertzahn noted its advancement in their proprietary development portfolio.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced its Q3 2021 results, highlighting a cash balance of US$11,266,187 and total assets of US$36,284,015. The company completed the acquisition of PsyTech, launching a new Care Delivery segment, and pledged US$1.5 million to MAPS for research on MDMA therapy for Traumatic Brain Injury (TBI). Wesana is positioned for growth with an expansion into clinical settings and was included in the AdvisorShares Psychedelics ETF.
FAQ
What is the current stock price of Wesana Health Holdings (WSNAF)?
What is the market cap of Wesana Health Holdings (WSNAF)?
